8-K current report · filed Nov 16, 2026

Larimar Therapeutics, Inc. (LRMR) 8-K Current Report: November 16, 2026

Item 2.02Item EX-99.1LRMR overview

Short answer

Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter fiscal 2026 results announced for period ended September 30, 2026.

Larimar Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter fiscal 2026 results announced for period ended September 30, 2026
  • Operational highlights included alongside financial results, with details in Exhibit 99.1
  • Investor focus: clinical-development progress, cash runway and spending trends disclosed in the accompanying release

Item EX-99.1 · Exhibit EX-99.1

  • Completed BLA submission for nomlabofusp, seeking accelerated approval using skin FXN as a potential surrogate endpoint
  • FDA acceptance targeted early 2027, with potential U.S. approval mid-2027 and launch targeted Q3 2027
  • FORWARD-FA global confirmatory Phase 3 enrolling, creating a key post-submission regulatory and clinical catalyst
  • Cash, equivalents and marketable securities $128.7 million at September 30, 2026, runway into late Q2 2027
  • Net loss $31.1 million, or $0.29 per share, versus $47.7 million, or $0.61, in Q3 2025; R&D fell to $25.9 million from $44.9 million

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Larimar Therapeutics, Inc. 8-K filings

Get the next LRMR 8-K as it lands

Follow LRMR for push alerts, or ask the research agent what this filing means.